JAMA: 2009-08-19, Vol. 302, No. 7, Author in the Room ™ Audio Interview
Interview with John Iskander, MD, author of Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine. Summary Points: 1. Since quadrivalent HPV vaccine was licensed in June 2006, more than 23 million doses have been administered nationally. 2. There were a total of 12,424 reports to the Vaccine Adverse Event Reporting System (VAERS) of adverse events following HPV vaccination through December 2008. The vast majority (94%) of adverse events reported to VAERS after receiving this vaccine have not been considered serious. The findings of this first published post-licensure safety review were...
Source: JAMA Author in the Room - October 23, 2009 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
JAMA: 2009-08-19, Vol. 302, No. 7, Author in the Room™ Audio Interview
Interview with John Iskander, MD, author of Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine. Summary Points: 1. Since quadrivalent HPV vaccine was licensed in June 2006, more than 23 million doses have been administered nationally. 2. There were a total of 12,424 reports to the Vaccine Adverse Event Reporting System (VAERS) of adverse events following HPV vaccination through December 2008. The vast majority (94%) of adverse events reported to VAERS after receiving this vaccine have not been considered serious. The findings of this first published post-licensure safety review were...
Source: JAMA Author in the Room - October 23, 2009 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
JAMA: 2007-08-15, Vol. 298, No. 7, Author in the Room Audio Interview
Interview with Douglas R. Lowy, MD, author of Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection. Summary Points: 1. The HPV vaccine has been shown to work very well in preventing new (incident) infection and disease caused by the HPV types targeted in the vaccine. 2. The JAMA study shows that HPV vaccination does not hasten clearance of existing (prevalent) infection with the HPV types targeted by the vaccine (HPV16 and 18). 3. It is most cost-effective to administer the vaccine before patients are exposed to HPV, because the vaccine is effective in preventing n...
Source: JAMA Author in the Room - September 19, 2007 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
The Lancet: May 18, 2007
Jorma Paavonen discusses the encouraging results of the human papilloma virus vaccine to protect against vulval and vaginal cancers. Jack Cuzick discusses findings highlighting an alternative approach to the treatment of early breast cancer. (Source: Listen to The Lancet)
Source: Listen to The Lancet - May 18, 2007 Category: General Medicine Authors: The Lancet Source Type: podcasts
Update on Pap tests
The launch of Australia's new vaccine for preventing certain strains of Human Papilloma Virus holds great promise in reducing the incidence of cervical cancer. But do we run the risk of missing tumors by slackening off on cervical cytology screening? Dr Stella Heley provides an update on Pap tests in this brave new world. (Source: Australian Family Physician audio)
Source: Australian Family Physician audio - February 28, 2007 Category: Primary Care Authors: The Royal Australian College Of General Practitioners Tags: Podcasts Source Type: podcasts
